Class information for:
Level 1: PSORIASIS//EFALIZUMAB//ALEFACEPT

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
2475 2163 32.9 74%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
669 12548 PSORIASIS//PSORIATIC ARTHRITIS//CALCIPOTRIOL

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PSORIASIS Author keyword 114 14% 35% 766
2 EFALIZUMAB Author keyword 60 57% 3% 70
3 ALEFACEPT Author keyword 51 69% 2% 44
4 USTEKINUMAB Author keyword 50 49% 3% 74
5 PSORIASIS AREA AND SEVERITY INDEX Author keyword 29 53% 2% 38
6 PSORIASIS DISABILITY INDEX Author keyword 20 100% 0% 9
7 DERMATOLOGY LIFE QUALITY INDEX Author keyword 19 40% 2% 36
8 DLQI Author keyword 17 51% 1% 24
9 PASI Author keyword 16 41% 1% 30
10 PLAQUE PSORIASIS Author keyword 13 40% 1% 26

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 PSORIASIS 114 14% 35% 766 Search PSORIASIS Search PSORIASIS
2 EFALIZUMAB 60 57% 3% 70 Search EFALIZUMAB Search EFALIZUMAB
3 ALEFACEPT 51 69% 2% 44 Search ALEFACEPT Search ALEFACEPT
4 USTEKINUMAB 50 49% 3% 74 Search USTEKINUMAB Search USTEKINUMAB
5 PSORIASIS AREA AND SEVERITY INDEX 29 53% 2% 38 Search PSORIASIS+AREA+AND+SEVERITY+INDEX Search PSORIASIS+AREA+AND+SEVERITY+INDEX
6 PSORIASIS DISABILITY INDEX 20 100% 0% 9 Search PSORIASIS+DISABILITY+INDEX Search PSORIASIS+DISABILITY+INDEX
7 DERMATOLOGY LIFE QUALITY INDEX 19 40% 2% 36 Search DERMATOLOGY+LIFE+QUALITY+INDEX Search DERMATOLOGY+LIFE+QUALITY+INDEX
8 DLQI 17 51% 1% 24 Search DLQI Search DLQI
9 PASI 16 41% 1% 30 Search PASI Search PASI
10 PLAQUE PSORIASIS 13 40% 1% 26 Search PLAQUE+PSORIASIS Search PLAQUE+PSORIASIS

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 TO SEVERE PSORIASIS 151 63% 7% 151
2 INFLIXIMAB INDUCTION 120 85% 3% 63
3 SEVERE PLAQUE PSORIASIS 113 57% 6% 132
4 INTERLEUKIN 12 23 MONOCLONAL ANTIBODY 111 44% 9% 190
5 CHRONIC PLAQUE PSORIASIS 93 33% 11% 235
6 EFALIZUMAB THERAPY 73 89% 2% 33
7 INTRAMUSCULAR ALEFACEPT 61 88% 1% 29
8 PLAQUE PSORIASIS 31 23% 6% 119
9 PLAQUE TYPE PSORIASIS 31 34% 3% 75
10 ALEFACEPT 27 54% 2% 35

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
PASI90 response: the new standard in therapeutic efficacy for psoriasis 2015 4 17 88%
Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials 2014 16 65 69%
European S3-Guidelines on the systemic treatment of psoriasis vulgaris 2009 224 211 38%
British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009 2009 169 181 43%
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics 2008 290 154 47%
Antidrug antibodies in psoriasis: a systematic review 2014 16 59 39%
What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature 2010 53 29 86%
What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature 2010 45 15 93%
Current severe psoriasis and the Rule of Tens 2005 153 43 84%
Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data 2012 28 50 68%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PSORIASIS 9 35% 1.0% 21
2 CENT DERMATOL 4 75% 0.1% 3
3 KLIN BEREICH DERMATOL 3 100% 0.1% 3
4 PSYCHODERMATOL 3 37% 0.3% 7
5 HLTH SERV DERMATOL NURSING IVDP 3 38% 0.3% 6
6 DERMATOL CLIN 3 3 60% 0.1% 3
7 DERMATOL IDI 3 60% 0.1% 3
8 PATHOL PUBL HLTH SCI 3 60% 0.1% 3
9 PSORIASIS SKIN TREATMENT 3 24% 0.5% 10
10 SECT CLIMATE THER Y 3 35% 0.3% 6

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000289218 UNIT MULTIDISCIPLINARY INVEST BIOMED//PSORIATIC NEPHROPATHY//DERMATOL VENEREOL PAEDIAT DERMATOL
2 0.0000181283 CALCIPOTRIOL//BETAMETHASONE DIPROPIONATE//TACALCITOL
3 0.0000169832 CHILDHOOD PSORIASIS//JUVENILE PSORIASIS//PERIANAL STREPTOCOCCAL DERMATITIS
4 0.0000159925 PATRICIA RITCHIE CANC CARE//EORTC QLQ C36//FEAR OF CANCER PROGRESSION
5 0.0000154596 PSORIATIC ARTHRITIS//PSORIAT ARTHRIT PROGRAM//PROGNOSIS STUDIES RHEUMAT DIS
6 0.0000145111 DRUG INDUCED LUPUS//DRUG INDUCED LUPUS ERYTHEMATOSUS//TNF ALPHA ANTAGONISTS
7 0.0000130958 PSORIASIS//TAIYUAN CITY HOSP//MOUSE TAIL TEST
8 0.0000102552 ACRODERMATITIS CONTINUA OF HALLOPEAU//VOCLOSPORIN//MICROEMULSION FORMULATION
9 0.0000089582 BATH PUVA//8 METHOXYPSORALEN//PUVA
10 0.0000089117 PIMECROLIMUS//ATOPIC DERMATITIS//TACROLIMUS OINTMENT